1. Short title This Act may be cited as the Opioid Advocacy Transparency Act of 2018 . 2. Additional covered recipients for transparency reports required of manufacturers of opioids (a) In general Section 1128G(e) of the Social Security Act (42 U.S.C. 1320a–7h(e)) is amended— (1) in paragraph (6)— (A) in subparagraph (A)— (i) in the matter preceding clause (i), by inserting and subject to subparagraph (C) after subparagraph (B) ; and (ii) by adding at the end the following new clause: (vi) A relevant patient advocacy organization (as defined in subparagraph (D)) or a foundation established by such an organization. ; and (B) by adding at the end the following new subparagraphs: (C) Limitation Clause (vi) of subparagraph (A) shall only apply with respect to information required to be submitted under this section by an applicable manufacturer that is the manufacturer of a covered drug, device, biological, or medical supply that is an opioid (as defined in section 102 of the Controlled Substances Act ( 21 U.S.C. 802 )). (D) Relevant patient advocacy organization For purposes of subparagraph (A)(vi), the term relevant patient advocacy organization means an organization engaged in advocacy on issues related to opioids (as so defined), including patient use of and access to opioids, the use of opioids for the treatment of pain, and opioid addiction treatment. ; and (2) in paragraph (10)(B)— (A) in clause (i), by striking A transfer and inserting Subject to clause (xiii), a transfer